Despite the importance of reproductive medicine to people's lives, it has been a singularly unrewarding area for new companies. The marketplace is dominated by a few big players: Johnson & Johnson (JNJ), Abbott Laboratories (ABT), Wyeth (WYE) and Serono S.A. (SWX:SEO; SRA). Ardana Ltd. thinks there is room for one more. The company is following a low-risk strategy of in-licensing and reformulating existing compounds for development in the European market, as well as repositioning off-patent niche products for reproductive indications.
Read the full 807 word article